Rexulti Prior Authorization: What You Need to Know: What to Know in 2026

Written By

Dan Nandan

25+ Years Healthcare Outsourcing. CEO, Staffingly

▼

Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.

2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.

Featured in Computerworld →

Clinically Reviewed By

Bincy Kuriakose, MSN, RN

Clinical Content Reviewer. IL RN License #041.577729

▼

State of Illinois. Registered Professional Nurse

Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.

Why Does Rexulti Require Prior Authorization?

• Rexulti (brexpiprazole) is an atypical antipsychotic manufactured by Otsuka and Lundbeck, first FDA-approved in 2015
• Three FDA-approved indications: (1) adjunctive treatment of MDD in adults, (2) schizophrenia in adults and adolescents 13+, (3) agitation associated with dementia due to Alzheimer’s disease (approved May 2023)
• Retail cost approximately $1,556-$1,833/month with no generic alternative available
• Medicare Part D places Rexulti on Tier 4 (non-preferred) or Tier 5 (specialty) in most formularies
• 83% of commercial insurance plans cover Rexulti, but many with restrictions
• PA is the payer’s mechanism to confirm: (1) documented diagnosis matching an FDA-approved indication, (2) medical necessity over lower-cost alternatives, (3) step therapy completion

Step-by-Step Guide to Securing Prior Authorization for Rexulti

Securing Rexulti prior authorization follows a repeatable six-step workflow, from confirming the patient’s plan and step-therapy rules through submission, status monitoring, and denial handling.

Step 1: Review the Patient's Insurance Plan

• Access the formulary to confirm Rexulti is covered and note its tier placement
• Check for step therapy guidelines. For MDD adjunct: plans typically require documented failure of both an antidepressant AND a generic atypical antipsychotic. For schizophrenia: usually requires failure of one generic atypical
• Use the Otsuka formulary checker or the plan's online tool to verify PA requirements before prescribing

Step 2: Gather All Necessary Documentation

• Patient diagnosis with ICD-10 codes aligned to Rexulti's FDA-approved indications
• Complete treatment history: list every previously prescribed medication with dates, doses, duration, and documented reason for discontinuation or failure
• Prescriber notes explaining why Rexulti is the best clinical option. Differentiate brexpiprazole from aripiprazole by receptor profile, tolerability, and clinical response
• Recent lab work if applicable (metabolic panel, liver function for safety monitoring)

Step 3: Obtain the Correct PA Form

• Each insurer has a specific PA form for Rexulti. Download from the insurer's website or request from the PBM
• Verify you are using the most current version of the form
• TRICARE has a specific brexpiprazole PA form available through the DoD pharmacy program

Step 4: Complete and Submit the PA Request

• Fill out all sections completely and accurately
• Attach all supporting documentation: diagnosis codes, treatment history, prescriber notes
• Submit via the insurer's preferred method (electronic portal is fastest, followed by fax)
• Keep copies of everything submitted

Step 5: Monitor the Status

• Standard PA decisions: 7 calendar days under CMS-0057-F (2026) for medical items; varies by plan for drugs
• Most drug PA decisions take 3-10 business days in practice
• Follow up after 3 days if no response
• For urgent cases, request expedited review (72-hour turnaround for urgent, 24-hour for Medicare Part D expedited)

Step 6: Handle Denials

• Review the denial letter for the specific reason
• Submit an appeal with additional clinical justification
• Request a peer-to-peer review with the payer's medical director
• Include peer-reviewed literature distinguishing brexpiprazole from aripiprazole if "therapeutic equivalent available" was the denial reason

ICD-10 and CPT Codes for Rexulti PA

• ICD-10 codes by indication:
• – MDD: F32.1 (moderate), F32.2 (severe without psychotic features), F32.3 (severe with psychotic features), F33.1 (recurrent, moderate), F33.2 (recurrent, severe)
• – Schizophrenia: F20.0 (paranoid), F20.1 (disorganized), F20.9 (unspecified)
• – Alzheimer’s agitation: F03.91 (unspecified dementia with behavioral disturbance), G30.9 (Alzheimer’s disease, unspecified)
• CPT code for drug administration: 96372 (therapeutic injection, specify substance)
• Accurate ICD-10 coding is the single most important factor in preventing PA rejections. 19% of Rexulti PA denials in the original blog data were attributed to incorrect or vague coding
• Always match the ICD-10 to the specific FDA-approved indication you are prescribing Rexulti for. Off-label indications will almost always be denied

How to Appeal a Rexulti Denial

• Common denial reasons: step therapy not documented (most frequent), incomplete clinical documentation, incorrect ICD-10 coding, formulary exclusion, quantity limit exceeded
• Level 1 Appeal (Redetermination for Medicare / Internal Appeal for Commercial):
• – Submit within 60 calendar days of denial (Medicare) or per plan timeline (commercial)
• – Include updated treatment history, letter of medical necessity, peer-reviewed literature supporting brexpiprazole’s distinct profile
• – Address the specific denial reason stated in the denial letter
• Peer-to-peer review: Request a call between the prescribing physician and the payer’s medical director. This is often the most effective appeal strategy for psychiatric medications where clinical nuance matters
• Level 2+ Appeals: Independent review entity (Medicare), external review (commercial), ALJ hearing, Medicare Appeals Council
• Mental Health Parity argument: If the payer applies PA requirements to Rexulti that are more restrictive than comparable medical/surgical medications, cite the Mental Health Parity and Addiction Equity Act (MHPAEA). The 2025 enforcement report found widespread payer non-compliance in this area
• Tip: For the Alzheimer’s agitation indication, include CMAI (Cohen-Mansfield Agitation Inventory) scores and document the specific safety concerns driving the need for pharmacological intervention. Payer criteria for this newer indication are still being established

Rexulti Coverage by State: New York, New Jersey, and California

New York

• NYRx Medicaid Pharmacy Program: Rexulti requires PA. Submit via phone (877) 309-9493 or fax to (800) 268-2990. PA updates effective February 19, 2026
• NYRx Preferred Drug Program manages the atypical antipsychotic class. Non-preferred agents like Rexulti require documented step therapy through a preferred generic
• Timothy's Law requires commercial plans to cover mental health on par with physical health, supporting PA appeals when step therapy is clinically inappropriate
• Medicare Advantage penetration approximately 45%, meaning nearly half of NY Medicare beneficiaries face MA-specific PA requirements

New Jersey

• NJ Medicaid (FamilyCare MCOs: Amerigroup, Horizon NJ Health, UHC Community Plan): Rexulti requires PA with step therapy through a generic atypical antipsychotic
• Horizon BCBSNJ (dominant commercial payer) requires PA with step therapy documentation
• NJ Mental Health Parity Act provides appeal use when Rexulti PA is denied for MDD or schizophrenia
• Staffingly is headquartered in Piscataway, NJ, with direct familiarity with NJ payer requirements

California

• Medi-Cal Rx manages the statewide drug formulary and PA criteria. Rexulti requires PA with step therapy
• California has approximately 15 million Medi-Cal enrollees, the largest Medicaid population in the U.S., creating massive PA volume for mental health medications
• SB 855 (2020) is one of the strongest mental health parity laws nationally, requiring commercial plans to cover all medically necessary mental health treatments. This is a strong basis for Rexulti PA appeals when generic alternatives have failed
• Major Medi-Cal managed care plans: Anthem Blue Cross, Health Net, Kaiser, L.A. Care, Molina

Rexulti vs Abilify: PA Comparison and Clinical Differences

• Aripiprazole (generic Abilify) is the most common step therapy requirement before Rexulti approval
• Both are atypical antipsychotics with D2 partial agonist activity, but they are NOT clinically interchangeable
• Key differences for PA documentation:

• When appealing a Rexulti denial after aripiprazole failure, document: specific adverse effects experienced on aripiprazole (akathisia, insomnia, restlessness), clinical response differences, and the distinct receptor binding profile of brexpiprazole

What Did We Learn?

• Rexulti PA is standard across commercial, Medicare, and Medicaid plans due to its brand-only status and $1,500+/month cost
• Clean submissions require: documented diagnosis with correct ICD-10 codes, step therapy documentation (generic atypical antipsychotic failure), letter of medical necessity differentiating brexpiprazole from aripiprazole
• PA requirements differ by indication: MDD adjunct requires the most step therapy layers, schizophrenia requires one generic trial, Alzheimer’s agitation criteria are still evolving
• Denials are common but frequently overturned on appeal, especially with peer-to-peer review and mental health parity arguments
• CMS-0057-F (2026) is pushing toward faster electronic PA decisions and mandatory denial reason transparency
• State variations matter: NY, NJ, and CA each have different Medicaid formularies, PA timelines, and mental health parity protections

Staffingly CTA: If Rexulti PAs are consuming your staff’s time and delaying patient care, Staffingly’s trained prior authorization specialists handle the entire submission, follow-up, and appeal process for you. Our team works across 50+ EHR platforms, processes PAs at a 99.2% clean claim rate, and costs $399/week (volume discounts to $299/week), saving practices up to 70% on staffing costs. 800+ healthcare providers trust Staffingly with their PA workload. Go live in 48-72 hours. SOC 2 Type II, HITRUST, ISO 27001, and HIPAA compliant.

What Psychiatrists Actually Say

Psychiatry practice managers on Reddit’s r/Psychiatry and r/medicalbilling repeat the same Rexulti PA themes: step-therapy walls on Medicare Part D that require aripiprazole failure documentation even when the patient has clear tolerability reasons for brand therapy, F32.x versus F33.x diagnostic coding mismatches, and Alzheimer’s agitation indications that payers are still inconsistently approving. A recurring solution is to build a prior-medication trial template that captures dose, duration, and specific adverse effects by name.

A 4-psychiatrist practice in Manhattan, NY built a standardized Rexulti documentation template citing MHPAEA and aripiprazole tolerability failure, and increased first-pass approvals from 41% to 78% within 60 days. A 3-provider geriatric psychiatry group in Newark, NJ specializing in Alzheimer’s agitation used the 2023 FDA approval data and NJ Medicaid’s supplemental rebate arrangement to get 12 previously-denied Rexulti PAs overturned through peer-to-peer review. A 6-provider community mental health center in Los Angeles, CA serving Medi-Cal managed care documented aripiprazole-induced akathisia by name in every Rexulti PA and cut denials from 62% to 14%.

For specialty psychiatric medications like Rexulti, the administrative burden of PA submissions, multi-layered step-therapy documentation, follow-ups, and denial appeals can consume 20-40 minutes per case. A dedicated prior authorization team can absorb that workload so clinicians spend their time on patients rather than payer paperwork.

Q1: Why does Rexulti require prior authorization? A: Rexulti (brexpiprazole) is a brand-name atypical antipsychotic with no generic alternative, costing approximately $1,556-$1,833/month at retail. Insurers require PA to confirm a documented diagnosis matching an FDA-approved indication, verify that the patient has tried and failed lower-cost alternatives (step therapy), and establish medical necessity. Medicaid plans require PA for 75% of enrollees, and most Medicare Part D plans also require PA.

Q2: What documentation do I need for a Rexulti PA submission? A: You need the patient’s diagnosis with matching ICD-10 codes (F32.x for MDD, F20.x for schizophrenia, G30.9/F03.91 for Alzheimer’s agitation), a complete treatment history showing prior medication trials with dates, doses, duration, and clinical reasons for discontinuation, a letter of medical necessity explaining why brexpiprazole is needed over generic aripiprazole or other alternatives, and prescriber NPI.

Q3: How long does Rexulti prior authorization take? A: Most insurers process Rexulti PA requests within 3-10 business days. Under CMS-0057-F (2026), expedited PA decisions must be issued within 72 hours for urgent requests. Medicare Part D expedited coverage determinations require a 24-hour turnaround when patient health is at immediate risk. Following up after day 3 is recommended.

Q4: What should I do if Rexulti PA is denied? A: File an appeal addressing the specific denial reason. Include additional clinical documentation and peer-reviewed literature distinguishing brexpiprazole from aripiprazole, and request a peer-to-peer review between the prescriber and the payer’s medical director. For Medicare, submit the Level 1 redetermination within 60 calendar days of the denial. Where PA rules are more restrictive than for comparable medical drugs, cite the Mental Health Parity and Addiction Equity Act (MHPAEA).

Frequently Asked Questions